nitroglycerin - Profile

What are the generic drug sources for nitroglycerin and what is the scope of freedom to operate?

Nitroglycerin is the generic ingredient in sixteen branded drugs marketed by Evus, Pohl Boskamp, Bausch, Valeant Pharms, Valeant Pharms North, Uspharma, Lannett Co Inc, Mylan Technologies, Zydus Pharms, Novartis, Sanofi Aventis Us, Abraxis Pharm, Am Regent, Hospira, Intl Medication, Luitpold, Smith And Nephew, Baxter Hlthcare, Rorer, Parke Davis, Cosette, Encube, Solaris Pharma Corp, Tp Anda Holdings, Abbvie, Fougera Pharms Inc, Padagis Israel, Actavis Labs Fl Inc, Aurobindo Pharma, Dr Reddys, Glenmark Speclt, Mankind Pharma, Natco, Rubicon Research, Sigmapharm Labs Llc, Viwit Pharm, and Viatris, and is included in fifty-six NDAs. There are two patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Nitroglycerin has twenty patent family members in nine countries.

There are three tentative approvals for this compound.

Summary for nitroglycerin

International Patents:	20
US Patents:	2
Tradenames:	16
Applicants:	37
NDAs:	56

Generic filers with tentative approvals for NITROGLYCERIN

Applicant	Application No.	Strength	Dosage Form
		0.2MG/HR	Film, Extended Release; Transdermal
		0.4MG/HR	Film, Extended Release; Transdermal
		0.6MG/HR	Film, Extended Release; Transdermal

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for NITROGLYCERIN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NITROLINGUAL PUMPSPRAY	Sublingual Spray	nitroglycerin	400 mcg/spray, 4.9 g and 12 g bottles	018705	1	2012-04-17
NITROSTAT	Sublingual Tablets	nitroglycerin	0.3 mg, 0.4 mg, and 0.6 mg	021134	1	2005-10-19

US Patents and Regulatory Information for nitroglycerin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Evus	NITROMIST	nitroglycerin	AEROSOL, METERED;SUBLINGUAL	021780-001	Nov 2, 2006		RX	Yes	Yes
Pohl Boskamp	NITROLINGUAL	nitroglycerin	AEROSOL;SUBLINGUAL	018705-001	Oct 31, 1985		DISCN	No	No
Bausch	MINITRAN	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	089773-001	Aug 30, 1996		DISCN	No	No
Valeant Pharms	MINITRAN	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	089771-001	Aug 30, 1996		DISCN	No	No
Valeant Pharms	MINITRAN	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	089774-001	Aug 30, 1996		DISCN	No	No
Valeant Pharms North	MINITRAN	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	089772-001	Aug 30, 1996		DISCN	No	No

Expired US Patents for nitroglycerin

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-001	Feb 27, 1996	4,812,313
Abbvie	RECTIV	nitroglycerin	OINTMENT;INTRA-ANAL	021359-001	Jun 21, 2011	7,189,761
Viatris	NITROSTAT	nitroglycerin	TABLET;SUBLINGUAL	021134-003	May 1, 2000	6,500,456
Evus	NITROMIST	nitroglycerin	AEROSOL, METERED;SUBLINGUAL	021780-001	Nov 2, 2006	5,869,082
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996	4,955,344
Novartis	TRANSDERM-NITRO	nitroglycerin	FILM, EXTENDED RELEASE;TRANSDERMAL	020144-004	Feb 27, 1996	4,954,344

International Patents for nitroglycerin

Country	Patent Number	Title	Estimated Expiration
Spain	2672261
Australia	2009224968	Long-term stable pharmaceutical preparation having the active ingredient glycerol trinitrate
Australia	2012219926	Stabilized granules containing glyceryl trinitrate
European Patent Office	2254552	PRÉPARATION PHARMACEUTIQUE À GRANDE STABILITÉ, CONTENANT LE PRINCIPE ACTIF TRINITRATE DE GLYCÉROL (LONG-TERM STABLE PHARMACEUTICAL PREPARATION HAVING THE ACTIVE INGREDIENT GLYCEROL TRINITRATE)
Poland	2678000
World Intellectual Property Organization (WIPO)	2012113564

Nitroglycerin: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Nitroglycerin, a longstanding cornerstone in cardiovascular therapy, particularly angina pectoris management, remains an essential medication globally. Its market value, driven by chronic disease prevalence, patent expirations, manufacturing supply chains, and regulatory landscapes, presents both challenges and opportunities for investors. This analysis explores the current market dynamics, projected financial trajectories, opportunities for innovation, and competitive positioning to guide stakeholders in strategic decision-making.

---

Introduction to Nitroglycerin

Nitroglycerin (chemical formula: C₃H₅N₃O₉) is a vasodilator that relaxes vascular smooth muscle, primarily used to relieve chest pain in angina. Originally developed in the 19th century, it’s included as a front-line therapy in acute coronary syndrome management.

Current Formulations and Market Focus

Formulation	Usage	Route of Administration	Market Share (%)	Key Features
Sublingual tablets	Acute angina relief	Sublingual	55	Rapid onset
Transdermal patches	Preventive therapy	Dermal	30	Steady plasma levels
Intravenous (IV)	Hospital use	IV infusion	10	Emergency/acute settings
Oral sustained-release	Chronic management	Oral	5	Less common

Market Size and Growth Drivers

• Global Market Value (2022): Estimated at USD 1.2 billion
• Growth Rate (2023-2030 CAGR): ~3-4% (Source: Grand View Research, 2022)
• Key Drivers:
  • Rising cardiovascular disease (CVD) prevalence
  • Aging populations
  • Expanding hospital and outpatient care facilities
  • Continued reliance on established therapies despite generics

---

Market Dynamics

Regulatory Environment

• Patent Landscape: Original patents expired in the late 20th century; thus, the market is dominated by generic manufacturers [[1]].
• Quality Standards: Strict manufacturing regulations (FDA, EMA) influence entry costs but also ensure product consistency.
• Innovation Policy: There is limited scope for reformulation due to patent expiry, but new delivery systems (e.g., controlled-release patches) are emerging.

Supply Chain Considerations

Issue	Impact	Mitigation Strategies
Raw Material Sourcing	Variability in nitroglycerin precursor availability	Diversify suppliers, alternative synthesis methods
Manufacturing Capacity	Potential bottlenecks	Investment in scalable production facilities
Regulatory Delays	Market access delays	Early engagement with authorities

Competitive Landscape

Key Players	Market Share (%)	Strategic Focus	Notable Initiatives
Pfizer	25	Innovative delivery systems	Transdermal formulations
Novartis	15	Cost-effective generics	Global manufacturing
Mylan (now part of Viatris)	20	Broad access	Price competitiveness
Others	40	Regional players	Niche formulations

Note: The market is highly commoditized with low differentiation, leading to price sensitivity.

---

Financial Trajectory Predictions

Revenue Forecasts (2023–2030)

Year	Estimated Market Revenue (USD billion)	Assumptions
2023	1.2	Baseline, steady demand
2025	1.35	Moderate growth; increased CVD prevalence
2027	1.5	Increase in outpatient adoption
2030	1.65	Market expansion, generics penetration stabilizing

Profitability Outlook

Aspect	Details	Influence Factors
Margins	Stable, but declining due to commoditization (~15-20%)	Intensity of competitive pricing
R&D Investment	Low; focus on manufacturing efficiency	High reliance on generics and existing formulations
Licensing & Partnerships	Limited but strategic collaborations for delivery innovations	Opportunities for niche markets

Opportunities and Risks

Opportunities	Risks
New delivery systems (e.g., transdermal patches with controlled-release)	Patent expiration pressures intensify price erosion
Regional market expansion (Asia-Pacific, Latin America)	Stringent regional regulations
Lifecycle management through combination therapies	Market saturation in mature markets
Strategic alliances for manufacturing	Supply chain disruptions (raw material constraints)

---

Comparison with Alternative Therapies

Alternative Drugs	Advantages	Limitations	Market Penetration (%)
Nicorandil	Dual-action vasodilator	Limited regulatory approval in some regions	5-10
Ranolazine	Chronic angina management	Costlier	8-12
Calcium channel blockers	Broad application	Side effect profile	15-20

Implication: Nitroglycerin holds residual dominance due to cost advantages and established efficacy in acute settings.

---

Key Market Trends

• Shift towards Combination Therapies: Combining nitrates with other cardiovascular agents for enhanced efficacy.
• Emerging Delivery Technologies: Development of controlled-release transdermal patches and novel formulations.
• Regulatory Streamlining: Faster approval for delivery system innovations to capture niche markets.
• Generic Price Pressures: Sustained drive for cost-reduction impacting profit margins.

---

Deep Dive: Investment Hotspots

Area	Rationale	Likely ROI	Timeline
Controlled-release transdermal patches	Improved patient compliance, innovative delivery	High	3–5 years
Regional market entry	Growing CVD burden, underserved populations	Moderate	2–4 years
Supply chain optimization	Cost reduction, risk mitigation	Short-term	1–2 years

---

Comparison with Other Cardiac Drugs

Parameter	Nitroglycerin	Isosorbide Dinitrate	Isosorbide Mononitrate
Onset of Action	Rapid (seconds to minutes)	Moderate (15–30 min)	Slow (30–60 min)
Duration	Short (30–60 min)	Longer (6–8 hours)	Long (12–24 hours)
Delivery Forms	Sublingual, transdermal, IV	Oral	Oral, sustained-release

Implication: Nitroglycerin’s rapid action maintains a unique niche, but sustained-release options face market competition.

---

Conclusion

Nitroglycerin’s market remains vital but faces challenges from patent expirations, market commoditization, and emerging delivery innovations. The next phase for investors entails focusing on technology-driven formulations, regional expansion, and supply chain efficiency. A measured approach that balances core product stability with innovation funding will maximize returns.

---

Key Takeaways

• The global nitroglycerin market is projected to grow at 3-4% CAGR through 2030, driven by aging populations and cardiovascular disease prevalence.
• Generics dominate, leading to intense price competition but also opportunities for innovation via new delivery systems.
• Investment strategies should prioritize development of controlled-release patches, regional market penetration, and supply chain resilience.
• Market saturation in mature regions pressures margins; focus on emerging markets and niche formulations for growth.
• Strategic partnerships can facilitate accelerated development of delivery innovations and market access.

---

FAQs

1. What are the main factors influencing the profitability of nitroglycerin products?
Profits are predominantly affected by generic price competition, manufacturing costs, regulatory compliance, and innovation in delivery systems.

2. How is the patent landscape affecting investment in nitroglycerin innovations?
Patent expirations have led to market saturation with generics, discouraging R&D for new chemical entities but encouraging development of improved delivery methods and combination therapies.

3. What regional opportunities exist for expanding nitroglycerin markets?
Emerging markets in Asia-Pacific, Latin America, and Africa offer growth potential due to rising CVD incidence and limited existing penetration.

4. How do advancements in delivery systems impact the market?
Innovative delivery systems like controlled-release patches can create premium product segments, improve patient compliance, and circumvent price erosion.

5. What are the main risks for investors in the nitroglycerin market?
Market saturation, regulatory delays for new formulations, raw material supply disruptions, and increasing competition from alternative therapies pose risks.

---

References

[1] Grand View Research. (2022). "Nitroglycerin Market Size, Share & Trends Analysis Report."